Floatz logo

Cefepime

Leukemia

Jonsson Comprehensive Cancer CenterSmall moleculePhase 3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
65/ 100

Competitive context

125 Active assets in the Leukemia cohort.

View all 50

Same molecule, other indications

Cefepime is also rated in:

neutropeniaDormant
BB
Indicative ·
70 / 100
View asset →
Pediatric CancerDormant
B
Indicative ·
62 / 100
View asset →
Invasive Bacterial InfectionDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →